Key result
Intravenous nifekalant hydrochloride effectively prevented refractory ventricular tachycardia/fibrillation without proarrhythmia or hemodynamic deterioration in 70% of treated patients.
Why the study?
Does intravenous nifekalant hydrochloride prevent refractory VT/VF in patients with acute coronary syndrome or chronic structural heart disease?
Observational (n=30)
Does intravenous nifekalant hydrochloride prevent refractory VT/VF in patients with acute coronary syndrome or chronic structural heart disease?
Intravenous nifekalant is effective for emergent treatment of drug-refractory VT/VF, though the risk of proarrhythmic torsade de pointes must be monitored.
Answers are grounded in this paper and cite their sources.
NIF may aid refractory VT/VF control with QT monitoring; leaves open need for RCTs versus established agents.
Nifekalant hydrochloride (NIF) is a novel intravenous class-III antiarrhythmic agent with a pirimidinedione structure that purely blocks the K+ channel without inhibiting beta-adrenergic receptors. The authors investigated the efficacy of NIF for refractory ventricular tachycardia/fibrillation (VT/VF). They studied 30 patients treated with an intravenous infusion of NIF [ 26 men, 4 women; age: 63 +/- 17 (mean +/- SD) years] at a dose of 0.19 +/- 0.14 mg/kg body weight per hour. Sixteen were patients with acute coronary syndrome (ACS), and 14 were patients with chronic structural heart disease (Chr-HD). Amiodarone and sotalol had already been administered to 9 patients with Chr-HD before the administration of NIF. The QT and T peak-end (Tp-e) intervals were measured and corrected by Bazett's method (QTc, cTp-e). The left ventricular ejection fraction was depressed (28 +/- 9%). NIF was effective for preventing VT/VF without proarrhythmia and hemodynamic deterioration in 21 patients (70%; 12 with ACS; 9 with Chr-HD), but ineffective in 4 patients (all with Chr-HD). The QTc prolongation in the responders was more pronounced than in the nonresponders (25% +/- 15% versus 5% +/- 7% increase; P < 0.05). Proarrhythmic torsade de pointes (TdP) developed transiently in the remaining 5 patients in whom the cTp-e was markedly increased compared with that in the responders (93% +/- 49% versus 37% +/- 41% increase; P < 0.05). In conclusion, these findings indicate that the intravenous administration of NIF is useful in the emergent treatment of inhibiting drug-refractory VT/VF, although proarrhythmic TdP owing to an enhancement of transmural dispersion of repolarization needs to be taken into account.
No takes yet. Share an insight, caveat, or question.
Ohashi et al. (2006) conducted an observational in Refractory ventricular tachycardia/fibrillation (VT/VF) (n=30). Nifekalant hydrochloride (NIF) was evaluated on Prevention of VT/VF without proarrhythmia and hemodynamic deterioration. Intravenous nifekalant hydrochloride effectively prevented refractory ventricular tachycardia/fibrillation without proarrhythmia or hemodynamic deterioration in 70% of treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: